Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-007806
Filing Date
2022-05-05
Accepted
2022-05-05 16:05:54
Documents
57
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ctmx-20220331.htm   iXBRL 10-Q 2308388
2 EX-31.1 ctmx-ex31_1.htm EX-31.1 20608
3 EX-31.2 ctmx-ex31_2.htm EX-31.2 20740
4 EX-32.1 ctmx-ex32_1.htm EX-32.1 14267
5 EX-32.2 ctmx-ex32_2.htm EX-32.2 14251
  Complete submission text file 0000950170-22-007806.txt   6897830

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctmx-20220331_def.xml EX-101.DEF 172978
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctmx-20220331_pre.xml EX-101.PRE 276588
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctmx-20220331_lab.xml EX-101.LAB 318666
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctmx-20220331_cal.xml EX-101.CAL 32917
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctmx-20220331.xsd EX-101.SCH 40670
51 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-20220331_htm.xml XML 1088311
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37587 | Film No.: 22896154
SIC: 2834 Pharmaceutical Preparations